PPARγ antagonists have been shown to have anti-obesity and anti-diabetic activity10, 11, 12, 13, suggesting that the inhibition of PPARγ activity may be beneficial to prevent obesity, steatosis and other metabolic disorders. This evidence concerns the gene PPARG and steatosis.